Acalabrutinib Cipla 100 mg Capsule
PDF Leaflet Revision Date: 04 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL).
Dosage (summary)
100 mg (1 capsule) twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid breastfeeding during treatment and for 2 days after last dose.
Key Drug Interactions
- Strong CYP3A inhibitors
- Strong CYP3A inducers
- Gastric acid reducing medicines
Contraindications
- Hypersensitivity to acalabrutinib or excipients
Common side effects
- Infection
- Headache
- Diarrhoea
- Bruising
- Fatigue
Counselling Points
- Take at the same time each day
- Do not chew or open capsules
- Monitor for signs of bleeding or infection
Serious warnings
- Serious haemorrhagic events
- Serious infections
- Cytopenias
- Atrial fibrillation
Important Disclaimer
The Acalabrutinib Cipla 100 mg Capsule professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
